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ABSTRACT
To reduce smoking-related diseases, a research priority is to develop effective 
interventions for smoking cessation, and evidence from randomized controlled trials 
(RCTs) is usually considered to be the most valid. However, findings from RCTs may 
still be misleading due to methodological flaws. This study aims to assess the quality 
of 1083 RCTs of smoking cessation interventions in 41 relevant Cochrane Systematic 
Reviews (CSRs). Logistic regression analysis was performed to identify significant 
variables associated with the quality of RCTs. It was found that evidence for smoking 
cessation from RCTs was predominantly from high income countries, and the overall 
quality was high in only 8.6% of the RCTs. High quality RCTs tended to have a larger 
sample size, to be more recently published, and conducted in multiple countries 
belonging to different income categories. In conclusion, the overall quality of RCTs of 
smoking cessation interventions is far from perfect, and more RCTs in less developed 
countries are required to generate high grade evidence for global tobacco control. 
Collaboration between researchers in developed and less developed countries should 
be encouraged.
INTRODUCTION
Tobacco use remains the leading preventable cause 
of premature deaths in the world, and smoking-related 
illness imposes a heavy economic toll on countries in both 
direct medical care and lost productivity [1]. While the 
prevalence of smoking has been declining in developed 
countries, cigarette smoking remains high, particularly 
among men, in less developed countries. The World Health 
Organization estimated that tobacco use is likely to cause 
over 8 million deaths per year in the next two decades, 
and more than 80% of these deaths will occur in low and 
middle income countries (LMICs) [2]. Therefore, one of 
research priorities is to develop and evaluate smoking 
cessation interventions, in order to prevent or reduce 
diseases attributable to tobacco use, in both developed and 
less developed countries.
Randomized controlled trials (RCTs) can provide 
valid evidence on the effectiveness of smoking cessation 
interventions. However, findings from RCTs may be 
misleading due to methodological flaws, including 
inappropriate patient allocation, lack of blinding, and 
imbalanced withdrawals from a study [3]. Risk of bias in 
RCTs should be carefully assessed, before applying results 
of RCTs to guide clinical and public health practice [4].
Previous studies found that most research on tobacco 
control were conducted in high-income countries [5, 6], 
and the quality of RCTs on non-communicable diseases in 
less developed countries tended to be lower than those in 
developed countries [7]. Evidence on the overall quality of 
RCTs on smoking cessation and associated factors remains 
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scarce. The main purpose of this study is to assess the 
quality of RCTs of smoking cessation interventions, and 
to identify associated factors.
RESULTS
The process of the selection of relevant Cochrane 
Systematic reviews (CSRs) is shown in Figure 1. The 
initial search identified 156 CSRs from a total of 9301 
records in the Cochrane Database of Systematic Reviews. 
We excluded 96 CSRs after screening their titles and 
abstracts, and excluded 19 CSRs after checking full text 
details. A total of 41 CSRs met the inclusion criteria and 
made up the dataset [8–48].
The main characteristics of the included CSRs are 
summarized in Table 1. Corresponding authors of the 
included CSRs were all from institutions in high-income 
countries. Smoking cessation interventions evaluated were 
behavioral therapy in 13 (31.7%), pharmaceutical aids 
in 6 (14.6%), psychosocial interventions in 5 (12.2%), 
tobacco control policies in 2 (4.9%), nicotine vaccines in 
1 (2.4%), self-help in 1 (2.4%), and mixed interventions 
in 13 (31.7%). Of the 41 CSRs, 28 (68.3%) were updated 
after 2012. The 41 CSRs included a total of 1083 RCTs. 
The median number of RCTs included in these CSRs was 
21 (interquartile range 7 to 35). Language restriction was 
explicitly applied in only three CSRs (including RCTs 
published in English or Chinese).
The main characteristics of RCTs and risk of 
specific biases
Of the 1083 RCTs included in the 41 CSRs, 96.1% 
were conducted in high-income countries, 2.8% in LMICs, 
and 1.1% in multiple-income countries (in both high-
income and LMICs) (Table 2). Most of the included RCTs 
were published in English (96.9%), and only 3.1% in other 
languages (Chinese, Japanese, French, Germany, etc.). 
Figure 1: Selection of relevant Cochrane Systematic Reviews (CSRs).
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For the 10 RCTs conducted in China, 6 were published 
in Chinese language. Sample sizes of the RCTs ranged 
from 9 to 42277 (median 280, interquartile range: 120 to 
719), and the sample size was ≥700 in 25% of the RCTs. 
The number of RCTs included in the CSRs was increasing 
over time, and more than half (62.3%) were published 
since 2000. Unpublished data were obtained for 92 of the 
included RCTs (8.5%).
The proportion of RCTs with a low risk of bias 
was 40.7% in terms of sequence generation, 30.6% in 
terms of allocation concealment, 23.4% in terms of 
blinding, 55.3% in terms of incomplete outcome, and 
10.6% regarding reporting bias (Table 2). The quality 
regarding to sequence generation, allocation concealment 
and incomplete outcome was similar for RCTs conducted 
in high-income countries and in LIMCs, although it was 
highest when studies were conducted in mixed-income 
countries (that is, in both developed and less developed 
countries). The quality tended to be higher for RCTs 
published in English, compared with those published 
in other languages. With certain exceptions, the quality 
of RCTs tended to be positively associated with larger 
sample sizes and more recent publications. The use of both 
published and unpublished data was associated with low 
risk of bias in terms of sequence generation and allocation 
concealment, although the association was not consistent 
for other quality domains (see Table 2).
Overall quality of RCTs and related factors
Defined as at least 4 of the 5 quality domains being 
low risk of bias, the overall quality was high in only 93 
Table 1: The characteristics of the included cochrane systematic reviews (CSRs)
 Number of CSRs (%)
Total 41
Country of CSR corresponding authors
  High-income countries 41 (100.0%)
Type of smoking cessation interventions  
  Policies 2 (4.9%)
  Behavioural therapy 13 (31.7%)
  Pharmaceutical quit aids 6 (14.6%)
  Nicotine vaccines 1 (2.4%)
  Psychosocial interventions 5 (12.2%)
  Self-help 1 (2.4%)
  Mixed 13 (31.7%)
Year of updated to:
  2010
  2011
  2012
  2013
  2014
2 (4.9%)
2 (4.9%)
9 (22.0%)
14 (34.1%)
8 (19.5%)
  2015 6 (14.6%)
Number of RCTs included:
  1 – 9
  10 – 19
  20 – 29
  30 – 39
  ≥40
13 (31.7%)
6 (14.6%)
9 (22.0%)
4 (9.8%)
9 (22.0%)
Any language restriction:
  No
  Yes
  Unclear
37 (90.2%)
3 (7.3%)
1 (2.4%)
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(8.6%) of the 1083 RCTs (Table 3). The proportion of high 
quality RCTs was 33.3% in RCTs conducted in multiple 
income countries, compared with 8.3% in RCTs from 
high-income countries and 10.0% in LMICs (P=0.008). 
There were no significant differences in the overall quality 
regarding the publication language (P=0.109) and data 
publication status (P=0.699) (Table 3). However, there was 
a clear association between the overall quality of RCTs 
and sample size (P=0.010). In addition, the proportion 
of high quality RCTs was noticeably increasing over 
time, from 1.5% in RCTs published before 1990, to 4.0% 
between 1990 and 1999, 10.7% between 2000 and 2009, 
and 14.7% since 2010 (P<0.001).
We performed multivariable logistic regression 
analysis to explore factors associated with the overall 
quality of RCTs (Table 4). The dependent variable was 
the high overall quality of RCTs, defined as at least four 
of the five bias items being low. The overall quality of 
RCTs was higher (that is, at low risk of bias) in RCTs with 
larger sample sizes (P=0.031), published more recently 
(P<0.001) and conducted in multiple countries belonging 
to different income categories (P=0.020).
DISCUSSION
Effects of smoking cessation treatments are usually 
small and relapse is common [49]. To improve the smoking 
cessation success, smokers who want to quit should 
be treated with the most effective smoking cessation 
interventions [50]. The CSRs included in the current study 
Table 2: The number and proportion of randomized controlled trials (RCTs) with low risk of bias by study characte
ristics
 Sequence 
generation
Allocation 
concealment Blinding
Incomplete 
outcome Reporting
Total (n=1083) 441(40.7%) 331(30.6%) 253(23.4%) 599(55.3%) 115(10.6%)
Country income levels
High-income (n=1041) 419(40.2%) 312 (30.0%) 242(23.2%) 574(55.1%) 108(10.4%)
LMICs (n=30) 12 (40.0%) 8 (26.7%) 7 (23.3%) 17 (56.7%) 3 (10.0%)
Multiple-income (n=12) 10 (83.3%) 11 (91.7%) 4 (33.3%) 8 (66.7%) 4 (33.3%)
Publication language of RCTs
English (n=1049) 437(41.7%) 328 (31.3%) 245(23.4%) 589(56.1%) 114(10.9%)
Other languages (n=34) 4 (11.8%) 3(8.8%) 8 (23.5%) 10(29.4%) 1 (2.9%)
Total sample size of RCTs
< 100 (n=215) 61 (28.4%) 38 (17.7%) 35 (16.3%) 102(47.4%) 37 (17.2%)
100 –299 (n=352) 155(44.0%) 108 (30.7%) 91 (25.9%) 192 (54.6%) 40 (11.4%)
300 – 699 (n=242) 108 (44.6%) 83 (34.3%) 64 (26.5%) 133 (55.0%) 18 (7.4%)
≥ 700 (n=274) 117 (42.7%) 102 (37.2%) 63 (23.0%) 172 (62.8%) 20 (7.3%)
Year of publication of RCTs
Before 1990 (n=135) 13 (9.6%) 12 (8.9%) 36 (26.7%) 60 (44.4%) 19 (14.1%)
1990-1999 (n=273) 66 (24.2%) 56 (20.5%) 55 (20.1%) 131 (48.0%) 14 (5.1%)
2000-2009 (n=484) 245 (50.6%) 185 (38.2%) 114(23.6%) 294 (60.7%) 51 (10.5%)
Since 2010 (n=191) 117 (61.3%) 78 (40.8%) 48 (25.1%) 114 (59.7%) 31 (16.2%)
Publication status
Published(n=991) 390 (39.4%) 292 (29.5%) 234(23.6)% 565 (57.0%) 103(10.4%)
Unpublished(n=11) 3 (27.3%) 3 (27.3%) 3 (27.3%) 4 (36.4%) 0 (0.0%)
Published and 
unpublished(n=81)
48 (59.3%) 36 (44.4%) 16 (19.8%) 30 (37.0%) 12 (14.8%)
Note: RCTs conducted in “multiple-income” refers to RCTs that recruited participants in both high-income countries and 
LMICs.
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Table 3: The characteristics of randomised controlled trials (RCTs) included in the cochrane systematic reviews 
(CSRs) by quality
 Overall quality of RCTs
χ2 P value
Low High
All included RCTs (1083) 990 (91.4%) 93 (8.6%)   
Country income levels     
High-income (n=1041) 955 (91.7%) 86 (8.3%) 9.578 0.008
LMICs (n=30) 27 (90.0%) 3 (10.0%)   
Multiple-income (n=12) 8 (66.7%) 4 (33.3%)   
Published in English     
Yes (n=1049) 956 (91.1%) 93 (8.9%) 3.297 0.109
No (n=34) 34 (100.0%) 0 (0.0%)   
Total sample size     
< 100 (n=215) 208 (96.7%) 7 (3.3%) 11.319 0.010
100 –299 (n=352) 322 (91.5%) 30 (8.5%)   
300 – 699 (n=242) 217 (89.7%) 25 (10.3%)   
≥ 700 (n=274) 243 (88.7%) 31 (11.3%)   
Year of publication     
Before 1990 (n=135) 133 (98.5%) 2 (1.5%) 27.748 <0.001
1990-1999 (n=273) 262 (96.0%) 11 (4.0%)   
2000-2009 (n=484) 432 (89.3%) 52 (10.7%)   
Since 2010 (n=191) 163 (85.3%) 28 (14.7%)   
Publication status     
Published(n=991) 908 (91.6%) 83 (8.4%) 0.718 0.699
Unpublished(n=11) 10 (90.9%) 1 (9.1%)   
Published and unpublished(n=81) 72 (88.9%) 9 (11.1%)   
Note: High quality research is defined as at least 4 of the 5 quality items being low risk of bias.
Table 4: Association between overall quality of RCTs and selected study characteristics: results of multi-variable 
logistic regression analysis
Variables Odds ratio (95% CI) P-value
Country income levels:
Multiple-income (1) vs. high-income or LMICs (0) 4.374 (1.259, 15.202) 0.020
Sample size:
Sample size ≥300 (1) vs. <300 (0) 1.625 (1.046, 2.523) 0.031
Year of publication:
Published since 2000 (1) vs. before 2000 (0) 3.888 (2.130, 7.099) <0.001
Note: Dependent variable is defined as at least 4 of the 5 quality items being low risk of bias (0 for high risk, 1 for low 
risk).
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evaluated a range of smoking cessation interventions, 
including behavioral, pharmacological, psychosocial, 
tobacco control policy, and mixed interventions.
RCTs may provide high-quality evidence, but they 
can also be graded down because of flaws in design, 
conduct and reporting. The current study found that less 
than 50% of the included RCTs had low risk of bias in 
specific quality domains, except for the bias due to 
incomplete outcome data (55.3%). It was noted that the 
proportion of RCTs with unclear or high risk of reporting 
bias was as high as 89.4%, indicating the existence of 
publication bias due to the tendency that significant results 
were more likely to be published [51–53].
In accordance with findings from previous studies 
[54, 55], the quality of the included RCTs has been 
improving over time, and was positively associated with 
a larger sample size. In addition, the quality of RCTs 
conducted in multiple nations belonging to different 
income groups was higher than those conducted in either 
high-income countries or in LMICs. However, the current 
study found no significant difference in quality between 
RCTs in LMICs and those in high-income countries, in 
contrast to findings from a previous study [7]. It should be 
acknowledged that the number of RCTs from LMICs in 
this study is very small (n=30), and reported quality may 
not necessarily reflect the true quality of trials [53].
This study found that most of the include RCTs 
were from high-income countries (96.1%), and were 
published in English (96.9%). The possible explanations 
include lack of research in LMICs, and researchers with 
English writing capability may have a strong presence 
in research activities for smoking cessation intervention. 
Even when studies had been conducted in LMICs and/
or by non-English speaking researchers, they might 
not be published, or published in journals that are not 
indexed in the widely used bibliographic databases such 
as MEDLINE and EMBASE. It is unclear whether and 
about the extent to which RCTs conducted in LMICs or 
published in languages other than English might have been 
missed from CSRs. Although the number of RCTs from 
LMICs (n=30) or published in non-English languages 
(n=34) was very small in the current study, we found no 
significant difference in quality between RCTs conducted 
in developed and less developed countries, and between 
RCTs published in English and those published in other 
languages.
Clearly, current smoking cessation and tobacco 
control practice in less developed LMICs will have 
to be based mainly on research from high-income 
developed countries. This raises a question about whether 
research evidence from high-income countries could be 
generalizable to LMICs. Generalizability or external 
validity of findings from RCTs is often context dependent, 
and questionable across different settings or countries [56, 
57]. For example, studies in the United States on average 
reported smaller effects of cardiorenal drugs compared 
with those conducted in other countries [58]. A study 
found that RCTs from less developed countries tended to 
report more favorable results than those from developed 
countries [53]. Because of doubtful generalizability of 
research from developed countries, evidence from local 
research may be more acceptable by health professionals 
in LMICs [59]. Scarce in evidence from RCTs will affect 
the local adoption and implementation of the interventions 
for smoking cessation in LMICs [60]. However, available 
evidence regarding the generalizability of research from 
developed to less developed countries is still very limited, 
and further research in this area is required.
Given the clear lack of relevant research in LMICs, 
it is important that more RCTs with high quality are 
conducted in LMICs to provide research evidence on 
smoking cessation interventions, which will contribute 
to improve representativeness and generalizability of 
high quality evidence from resources poor settings, 
and to encourage the researchers’ endeavor in tackling 
tobacco epidemic in LMICs. For researchers in LMICs, 
poor access to research funding and challenges with 
the publication of research may hinder their research 
activities. The development of research capacity in less 
developed countries will contribute to the control of 
diseases globally. Although the flow of research evidence 
is currently mainly from developed to less developed 
countries, it has been recently emphasized that high 
quality research in LMICs may also benefit developed 
countries [61]. According to findings from the current 
study and a previous study [7], collaboration between 
researchers in developed and less developed countries 
will be more likely to generate higher quality evidence. 
International and national research funding bodies need to 
encourage and support more studies of smoking cessation 
and tobacco control that are collaboratively conducted by 
researchers in developed and less developed countries.
Limitations
We only assessed RCTs included in Cochrane 
systematic reviews, and some relevant RCTs of smoking 
cessation interventions might have been missed. For 
example, the CSRs may have excluded some low quality 
RCTs from LMICs and non-English speaking countries 
that mislabeled study designs or did not adhere to the 
CONSORT guidelines for reporting [62]. If this is the 
case, our analysis may have overestimated the quality of 
RCTs on smoking cessation. The assessment of quality and 
risk of bias was based on what is reported by authors, and 
the actual conduct may be different. In addition, we did 
not analysis the primary outcome on smoking cessation 
interventions, which will be the focus of a further study.
CONCLUSION
The evidence from RCTs was predominantly from 
high income countries and published in English language. 
The overall quality of RCTs of smoking cessation 
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interventions is far from perfect, and the quality of RCTs 
was positively associated with a larger sample size and 
more recent years of publication. More RCTs with low 
risk of bias are required in LMICs to generate high 
grade evidence for global tobacco control. Collaboration 
between researchers in developed and less developed 
countries should be encouraged.
MATERIALS AND METHODS
Search methods for identifying studies
Cochrane Database of Systematic Reviews in 
Cochrane Library (Issue 3 of 12, 2016) was searched 
to identify eligible CSRs. The search strategy used the 
following combination terms: 'smok* OR tobacco OR 
cigarette* OR nicotine' in Title, Abstract, or Keywords. 
Identified CSRs were transferred into an Endnote 
database.
Selection of studies
Figure 1 shows the process of selection of CSRs. 
We first examined titles and abstracts of CSRs, and then 
checked full text details for those that were possibly 
eligible. Eligible CSRs were those updated since 2010 
and evaluated smoking cessation interventions for current 
smokers. We exclude CSRs that focused on interventions 
exclusively for passive smoking, and interventions for 
the primary prevention of tobacco use. There was no 
restriction on the length of follow up and the primary 
outcome measures. Two researchers (HF and JW) applied 
the inclusion and exclusion criteria to select relevant 
CSRs, and a third reviewer (FS) was involved when it was 
difficult to decide the eligibility of a CSR.
Data extraction and management
Data extraction was conducted by two researchers (JS 
and LW) and then checked by a third researcher (HF). Any 
disagreement was resolved by discussion. We extracted 
data on the following items from the included CSRs:
• Year as up-to-date
• Country of the corresponding author of CSRs
• Language restrictions for study inclusion
• Type of smoking cessation interventions
From RCTs included in the CSRs, we extracted data on the 
following elements:
• Year of publication
• Sample size
• Country origin
• Publication language
• Publication status
• Results of risk of bias assessment
Assessment of risk of bias in included RCTs
Risk of bias in all RCTs included in CSRs was 
assessed in terms of six quality domains: (1) the adequacy 
of sequence generation, (2) allocation concealment, (3) 
blinding of patients, care providers and outcome assessors, 
(4) incomplete outcome data, (5) free of selective outcome 
reporting, and (6) free of other bias, using the Cochrane 
Collaboration’s tool for assessing risk of bias [4]. For each 
of the six domains, risk of bias could be judged as being 
high, low, or unclear. Because risk of other biases (the 
last item) was inconsistently assessed in CSRs, we used 
results of risk of bias assessment for the first five domains. 
In this study, the quality of a RCT was considered to be 
high, if risk of bias was low for at least 4 of the 5 quality 
domains.
Data synthesis and analysis
We summarized the extracted data from the 
included CSRs and RCTs by tabulations. RCTs included 
in the relevant CSRs were grouped by trial characteristics. 
According to the gross national income (GNI) per capita 
in 2014, the World Bank currently classified countries as 
high-income (≥$12,736), middle-income (from $1,046 
to $12,735), and low-income (≤$1,045) [63]. Because of 
the small number of RCTs from low-income and middle-
income countries, we combined low-income and middle-
income countries as low-and-middle-income countries 
(LMICs) in analysis.
Normality of distribution was determined using 
QQ plots and Kolmogorov–Smirnov test. For the 
comparison of categorical variables, Pearson's chi-
square test or Fisher’s exact test was used as appropriate. 
To explore the factors associated with risk of bias of 
included RCTs, we conducted multi-variable logistic 
regression analyses. Two-tailed P values of less than 
0.05 were considered statistically significant. In the 
logistic regression model, we adopted the Enter Method 
to achieve a final model. The standard for the variable 
inclusion was based on SLE=0.05, and the exclusion 
standard was SLS=0.10. All data were processed using 
the program SPSS 18.0 (SPSS, Inc., Chicago, IL, USA) 
and Epidata 3.1.
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